ERBB2突变:非鳞状宫颈癌中有前景的治疗靶点
在1015例浸润性宫颈癌样本中采用基于cDNA的Sanger测序检测ERBB2、KRAS和PIK3CA突变,ERBB2体细胞突变率为3.15%,在腺癌、腺鳞癌和神经内分泌癌中的突变率显著高于鳞癌(P=0.004),ERBB2突变患者预后趋势介于KRAS突变与野生型/PIK3CA突变之间。
要点
- ERBB2体细胞突变在浸润性宫颈癌中检出率为3.15%。
- 腺癌、腺鳞癌和神经内分泌癌的ERBB2突变率显著高于鳞癌(P=0.004)。
- 18.75%的ERBB2突变患者同时携带PIK3CA或KRAS突变。
核心结论
- 本研究为酪氨酸激酶抑制剂治疗ERBB2突变宫颈癌的临床研究提供了有前景的依据。
- 非鳞状细胞癌患者应优先作为ERBB2靶向治疗的候选者。
- 在设计临床试验时应考虑并存的PIK3CA/RAS突变。
研究设计与样本
- 研究纳入1015例浸润性宫颈癌样本,采用基于cDNA的Sanger测序检测ERBB2、KRAS和PIK3CA突变。
主要发现
- ERBB2体细胞突变检出率为3.15%。
- ERBB2突变率在腺癌为4.52%(7/155)、腺鳞癌为7.59%(6/79)、神经内分泌癌为10.34%(3/29),均显著高于鳞癌的2.14%(16/749)(P=0.004,Fisher精确检验)。
- 18.75%的ERBB2突变患者同时携带PIK3CA或KRAS突变。
- ERBB2突变宫颈癌患者的预后倾向于差于野生型或PIK3CA突变患者,但好于KRAS突变患者。
临床怎么用
- 作者认为,本研究为非鳞状宫颈癌患者优先接受ERBB2靶向治疗提供了依据,并建议在设计临床试验时考虑并存的PIK3CA/RAS突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ERBB2 mutations have been found in a subset of invasive cervical cancer (ICC). Nevertheless, the prevalence, mutation spectrum, clinicopathological relevance, human papillomavirus (HPV)-genotype association and prognostic significance of ERBB2-mutated ICCs have not been well established. METHODS: In this study, ICC samples (N=1015) were assessed for mutations in ERBB2, KRAS, and PIK3CA by cDNA-based Sanger sequencing. RESULTS: Somatic ERBB2 mutations were detected in 3.15% patients. The ERBB2 mutation rate was significantly higher in adenocarcinoma (4.52%, 7/155), adenosquamous carcinoma (7.59%, 6/79) and neuroendocrine carcinoma (10.34%, 3/29) than that in squamous carcinoma (2.14%, 16/749) (P=0.004, Fisher exact test). In addition, 18.75% of the patients carrying ERBB2 mutations concomitantly harbored PIK3CA or KRAS mutations. Patients with ERBB2-mutated ICCs tended to have a worse prognosis than those with wild-type or PIK3CA-mutated ICCs but a better prognosis than those with KRAS-mutated ICCs. CONCLUSIONS: This study provided a promising rationale for the clinical investigation of tyrosine kinase inhibitors for the treatment of cervical cancer with ERBB2 mutations. Patients with non-squamous cell carcinomas have priority as candidates for ERBB2-targeted therapy. Concurrent PIK3CA/RAS mutations should be considered in the design of clinical trials.
引用
- Xiang L, Jiang W, Ye S, et al. ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecol Oncol. 2017. PMID: 29279289. doi:10.1016/j.ygyno.2017.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。